Maze Therapeutics's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 91.25.
Maze Therapeutics's Days Inventory for the
three
months ended in Mar. 2026 was .
Maze Therapeutics's Days Payable for the
three
months ended in Mar. 2026 was .
Therefore, Maze Therapeutics's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 91.25.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Maze Therapeutics Cash Conversion Cycle Related Terms
Maze Therapeutics Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Maze Therapeutics's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MAZE vs AVBP, DMRA, CAPR: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Maze Therapeutics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maze Therapeutics Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maze Therapeutics's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Maze Therapeutics's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Maze Therapeutics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maze Therapeutics (MAZE) has a Cash Conversion Cycle of 91.25 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Maze Therapeutics and its competitors.
Is Maze Therapeutics' Cash Conversion Cycle too high?
Maze Therapeutics' current Cash Conversion Cycle is 91.25. The Biotechnology industry median Cash Conversion Cycle is 102.77. Maze Therapeutics' value of 91.25 is 11.2% below this industry median. Overall, Maze Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' Cash Conversion Cycle compare to AVBP and DMRA?
Maze Therapeutics' Cash Conversion Cycle of 91.25 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 102.77. Maze Therapeutics' value of 91.25 is 11.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 102.77, based on 872 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maze Therapeutics's current Cash Conversion Cycle of 91.25 is 11.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Maze Therapeutics and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 102.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maze Therapeutics's current Cash Conversion Cycle is 91.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current Cash Conversion Cycle of 91.25. The current Cash Conversion Cycle is 91.25 and 11.2% below the Biotechnology industry median of 102.77. Maze Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current Cash Conversion Cycle is 91.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
14GF Score
Get the complete analysis for MAZE
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAZE has been successfully added to your 
